Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReBeL study in relapsed follicular lymphoma
NL-OMON47678Phase 2Completed
- Sponsor
- HOVON
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL) comparing Lenalidomide + rituximab with Lenalidomide + rituximab + bendamustine (2 arms). Primary endpoints: Dose limiting toxicity, Recommended dose level and 2 more. Started Sep 2011; status: completed.
02
Drugs
lenalidomiderituximabbendamustine
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON47678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47678.